Clinical Trials at Sydney Retina


Sydney Retina has committed to advancing ophthalmic care through high‑quality clinical research over several decades. We actively participate in international clinical trials to help develop new therapies and treatment approaches. Our previous contributions have subsequently led to approved treatments which has changed the standard of care for many ocular diseases and helped to reduce treatment burdens for existing patients.



Sydney Retina is involved in clinical research across all phases, from early safety studies to real‑world outcome evaluations. Our research team is dedicated to support innovation while delivering meaningful real‑world outcomes for our patients. We are actively participating in several international clinical trials supporting patients with age-related macular degeneration, diabetic eye disease, and retinal vein occlusions. 


Current Recruiting Trials


4FRONT-2 (4D-150-C004) gene therapy for wet AMD

  • This is a Phase 3 study to investigate the efficacy of a single gene therapy injection of 4D-150 compared to Aflibercept 2mg every 8 weeks.
  • Study Duration: 2 years


Vantage (Non-proliferative diabetic retinopathy (NPDR)

  • This is a Phase 2 study to evaluate the efficacy and safety of oral VX01 compared with placebo tablets for treatment of non-proliferative diabetic retinopathy (NPDR).
  • Study Duration: 1 year


Sanofi (Gene Therapy for geographic atrophy)

  • This is a Phase 1/2 study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR446597 (gene-therapy) in participants with geographic atrophy (GA).
  • Study Duration: 2 years (additional optional follow up for 3 years)


Upcoming Trials


Malbec (Injection for wet AMD)

  • This is a Phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE201/MK-8748 compared to Aflibercept 2 mg in participants with neovascular age-related macular degeneration.
  • Study Duration: 2 years


Helios-3 (Axitinib implant for Non-proliferative diabetic retinopathy)

  • Phase 3 study to evaluate safety and efficacy of intravitreal OTX-TKI (Axitinib implant) in participants with non-proliferative diabetic retinopathy (NPDR).
  • Study Duration: 2 years


Kriya-825-101 (Gene therapy for geographic atrophy)

  • This is a Phase 1/2 study to evaluate the safety, tolerability, and efficacy of one-time suprachoroidal injection of Adeno-associated Virus Vector VV-14295 in participants.
  • Study Duration: 1 year


Metagone (Implant for geographic atrophy)

  • This is a Phase 1/2a study to evaluate the safety, tolerability and efficacy after one-time intravitreal implant administration of TO-O1007 in participants.
  • Total Duration: 28 weeks


Sienna (Subcutaneous injection for geographic atrophy)

  • This is Phase 3 study to evaluate the efficacy, safety, and tolerability of subcutaneously administered poxelimab in combination with cemidisiran or cemidesiran alone in participants.
  • Study Duration: 2 years + optional long term treatment period (3 yrs)


To find out how our ongoing research supports advanced eye care and treatment outcomes, contact 02 9221 3755 to arrange a consultation with our specialist team.